Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease
Gespeichert in:
| Titel: | Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease |
|---|---|
| Autoren: | Pinto, Serge, Nebel, Adelheid, Rau, Jörn, Espesser, Robert, Maillochon, Pauline, Niebuhr, Oliver, Krack, Paul, Witjas, Tatiana, Ghio, Alain, Cuartero, Marie‐charlotte, Timmermann, Lars, Schnitzler, Alfons, Hesekamp, Helke, Meier, Niklaus, Müllner, Julia, Hälbig, Thomas, Möller, Bettina, Paschen, Steffen, Paschen, Laura, Volkmann, Jens, Barbe, Michael, Fink, Gereon, Becker, Johannes, Reker, Paul, Kühn, Andrea, Schneider, Gerd‐helge, Fraix, Valérie, Seigneuret, Eric, Kistner, Andrea, Rascol, Olivier, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Hartmann, Christian, Wojtecki, Lars, Fradet, Anne, Maltête, David, Damier, Philippe, Le Dily, Séverine, Sixel-Döring, Friederike, Benecke, Petra, Weiss, Daniel, Wächter, Tobias, Pinsker, Marcus, Régis, Jean, Thobois, Stéphane, Polo, Gustavo, Houeto, Jean‐luc, Hartmann, Andreas, Knudsen, Karina, Vidailhet, Marie, Schüpbach, Michael, Deuschl, Günther |
| Weitere Verfasser: | Pinto, Serge, Laboratoire Parole et Langage (LPL), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel (CAU), Philipps Universität Marburg = Philipps University of Marburg, GIN Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Neurologie, maladies neuro-musculaires Hôpital de la Timone - APHM, Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), University Hospital of Cologne Cologne, Heinrich Heine Universität Düsseldorf = Heinrich Heine University Düsseldorf, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre d'investigation clinique Paris Est CHU Pitié Salpêtrière (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Free University of Berlin (FU), Toulouse NeuroImaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Département Neurologie CHU Toulouse, Pôle Neurosciences CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402), Université de Poitiers = University of Poitiers (UP)-Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Paracelsus-Elena-Klinik, Kassel, Germany., Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = University of Tübingen, Universitäts Klinikum Freiburg = University Medical Center Freiburg (Uniklinik), Hôpital neurologique et neurochirurgical Pierre Wertheimer CHU - HCL, Hospices Civils de Lyon (HCL) |
| Quelle: | Movement Disorders. 38:212-222 |
| Verlagsinformationen: | Wiley, 2022. |
| Publikationsjahr: | 2022 |
| Schlagwörter: | speech, Parkinson's disease, Movement, Deep Brain Stimulation, MESH: Movement, 03 medical and health sciences, MESH: Deep Brain Stimulation / methods, 0302 clinical medicine, dysarthria, Subthalamic Nucleus, Humans, MESH: Speech Intelligibility / physiology, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Prospective Studies, [SHS.LANGUE]Humanities and Social Sciences/Linguistics, MESH: Treatment Outcome, subthalamic nucleus, MESH: Humans, Speech Intelligibility, Parkinson Disease, MESH: Subthalamic Nucleus / physiology, [SHS.LANGUE] Humanities and Social Sciences/Linguistics, MESH: Prospective Studies, deep brain stimulation, 3. Good health, Treatment Outcome, MESH: Parkinson Disease* / complications, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] |
| Beschreibung: | BackgroundThe EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN‐DBS) and best medical treatment (BMT) was superior to BMT alone.ObjectiveThis prospective, ancillary study on EARLYSTIM compared changes in blinded speech intelligibility assessment between STN‐DBS and BMT over 2 years, and secondary outcomes included non‐speech oral movements (maximum phonation time [MPT], oral diadochokinesis), physician‐ and patient‐reported assessments.MethodsSTN‐DBS (n = 102) and BMT (n = 99) groups underwent assessmentson/offmedication at baseline and 24 months (in four conditions:on/offmedication, ON/OFF stimulation—for STN‐DBS). Words and sentences were randomly presented to blinded listeners, and speech intelligibility rate was measured. Statistical analyses compared changes between the STN‐DBS and BMT groups from baseline to 24 months.ResultsOver the 2‐year period, changes in speech intelligibility and MPT, as well as patient‐reported outcomes, were not different between groups, eitherofforonmedication or OFF or ON stimulation, but most outcomes showed a nonsignificant trend toward worsening in both groups. Change in oral diadochokinesis was significantly different between STN‐DBS and BMT groups,onmedication and OFF STN‐DBS, with patients in the STN‐DBS group performing slightly worse than patients under BMT only. A signal for clinical worsening with STN‐DBS was found for the individual speech item of the Unified Parkinson's Disease Rating Scale, Part III.ConclusionAt this early stage of the patients' disease, STN‐DBS did not result in a consistent deterioration in blinded speech intelligibility assessment and patient‐reported communication, as observed in studies of advanced Parkinson's Disease. © 2022 The Authors.Movement Disorderspublished by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Publikationsart: | Article |
| Dateibeschreibung: | application/pdf; pdf |
| Sprache: | English |
| ISSN: | 1531-8257 0885-3185 |
| DOI: | 10.1002/mds.29282 |
| DOI: | 10.15496/publikation-94351 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/36461899 https://hal.science/hal-03900805v1/document https://hal.science/hal-03900805v1 https://doi.org/10.1002/mds.29282 |
| Rights: | CC BY |
| Dokumentencode: | edsair.doi.dedup.....aeae006c89cde3cf9af9998b08b4e56c |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | BackgroundThe EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN‐DBS) and best medical treatment (BMT) was superior to BMT alone.ObjectiveThis prospective, ancillary study on EARLYSTIM compared changes in blinded speech intelligibility assessment between STN‐DBS and BMT over 2 years, and secondary outcomes included non‐speech oral movements (maximum phonation time [MPT], oral diadochokinesis), physician‐ and patient‐reported assessments.MethodsSTN‐DBS (n = 102) and BMT (n = 99) groups underwent assessmentson/offmedication at baseline and 24 months (in four conditions:on/offmedication, ON/OFF stimulation—for STN‐DBS). Words and sentences were randomly presented to blinded listeners, and speech intelligibility rate was measured. Statistical analyses compared changes between the STN‐DBS and BMT groups from baseline to 24 months.ResultsOver the 2‐year period, changes in speech intelligibility and MPT, as well as patient‐reported outcomes, were not different between groups, eitherofforonmedication or OFF or ON stimulation, but most outcomes showed a nonsignificant trend toward worsening in both groups. Change in oral diadochokinesis was significantly different between STN‐DBS and BMT groups,onmedication and OFF STN‐DBS, with patients in the STN‐DBS group performing slightly worse than patients under BMT only. A signal for clinical worsening with STN‐DBS was found for the individual speech item of the Unified Parkinson's Disease Rating Scale, Part III.ConclusionAt this early stage of the patients' disease, STN‐DBS did not result in a consistent deterioration in blinded speech intelligibility assessment and patient‐reported communication, as observed in studies of advanced Parkinson's Disease. © 2022 The Authors.Movement Disorderspublished by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
|---|---|
| ISSN: | 15318257 08853185 |
| DOI: | 10.1002/mds.29282 |